Google's Entry Shifts the Personalized Medicine Tipping Point to The Edge | Diaceutics

Google’s Entry Shifts the Personalized Medicine Tipping Point to The Edge

September 23rd, 2013

Peter Keeling

Peter Keeling of Diaceutics comments on Google’s announcement that it will create Calico, a new type of company focused on disease management, and highlights how it is a game changer in the personalized medicine space.

At an offsite meeting of Diaceutics management team some two years ago, we defined a small number of events which would signal a tectonic shift towards a predominantly personalized model for the pharmaceutical and diagnostic industries. Since that time two of the events have already occurred: the $1000 genome and the realization of accelerated FDA approvals for biomarker-targeted therapies. A third was revealed over the past few days [2013] and it’s called Calico. See news here – http://www.latimes.com/business/la-fi-google-aging-20130919,0,6335069.story.

Calico is Google’s second venture into health care (remember their first, the failed Google Health EHR initiative?) and this time it is to build a new type of company focused on disease management. Details are scant about how Calico will go about its business, but we should not be waylaid by the absence of details at this stage since what is more important is to focus on the four huge competitive advantages Google collectively have over most other pharmaceutical incumbents:

  1. They have Art Levinson, formerly CEO of Genentech and a personalized medicine veteran, to lead the business. Unlike most pharma CEOs, Art Levinson has extensively leveraged the power of targeted therapy and diagnostic integration to transform patient pathways.
  2. As we discussed previously in What Minerva Knows That Pharma Doesnt Know Yet, Google have the competitive power and business model savvy to deliver a systems-integrated approach to disease management and only this integration approach will deliver the much promised personalized medicine revolution.
  3. Thirdly, they have the deep pockets required to enter the high barrier pharmaceutical world. Whilst Art Levinson and Google may decide to not buy AstraZeneca as we mooted here (https://www.diaceutics.com/?expert-insight=future-of-healthcare-is-personalized-medicine), we can rest assured that they will not tread water for the eight to ten years it takes to develop novel therapies. It is noted that Google Ventures are already significant stakeholders in Foundation Medicine.
  4. Finally, Google’s business is built around direct to consumer (read patient) interaction and all of us close to personalized medicine recognize that it is the patient who will ultimately drive the transformation to control their own personal health. In short, Google is already patient (not physician) centric.

For these reasons, Calico is a personalized medicine game changer.

Blogs

View all blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn